Last reviewed · How we verify
TNF-α inhibitor OR JAK inhibitor
TNF-α inhibitor OR JAK inhibitor is a Small molecule drug developed by Vastra Gotaland Region. It is currently in Phase 1 development. Also known as: TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi), JAK-inhibitors: Baricitinib (Olumiant), Tofacitinib (Xeljanz).
At a glance
| Generic name | TNF-α inhibitor OR JAK inhibitor |
|---|---|
| Also known as | TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi), JAK-inhibitors: Baricitinib (Olumiant), Tofacitinib (Xeljanz) |
| Sponsor | Vastra Gotaland Region |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (PHASE1)
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (PHASE2)
- Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications (PHASE1, PHASE2)
- Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)
- Baricitinib for Reduction of HIV - CNS (PHASE2)
- Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNF-α inhibitor OR JAK inhibitor CI brief — competitive landscape report
- TNF-α inhibitor OR JAK inhibitor updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI
Frequently asked questions about TNF-α inhibitor OR JAK inhibitor
What is TNF-α inhibitor OR JAK inhibitor?
TNF-α inhibitor OR JAK inhibitor is a Small molecule drug developed by Vastra Gotaland Region.
Who makes TNF-α inhibitor OR JAK inhibitor?
TNF-α inhibitor OR JAK inhibitor is developed by Vastra Gotaland Region (see full Vastra Gotaland Region pipeline at /company/vastra-gotaland-region).
Is TNF-α inhibitor OR JAK inhibitor also known as anything else?
TNF-α inhibitor OR JAK inhibitor is also known as TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi), JAK-inhibitors: Baricitinib (Olumiant), Tofacitinib (Xeljanz).
What development phase is TNF-α inhibitor OR JAK inhibitor in?
TNF-α inhibitor OR JAK inhibitor is in Phase 1.
Related
- Manufacturer: Vastra Gotaland Region — full pipeline
- Also known as: TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi), JAK-inhibitors: Baricitinib (Olumiant), Tofacitinib (Xeljanz)
- Compare: TNF-α inhibitor OR JAK inhibitor vs similar drugs
- Pricing: TNF-α inhibitor OR JAK inhibitor cost, discount & access